SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-23-000003
Filing Date
2023-01-05
Accepted
2023-01-05 16:35:25
Documents
12
Period of Report
2022-12-29
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20221229.htm   iXBRL 8-K 38174
  Complete submission text file 0001640455-23-000003.txt   173673

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20221229.xsd EX-101.SCH 1903
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20221229_lab.xml EX-101.LAB 23832
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20221229_pre.xml EX-101.PRE 12512
6 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20221229_htm.xml XML 10844
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 23511953
SIC: 2836 Biological Products, (No Diagnostic Substances)